Mannkind reported $-23239000 in EBIT for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Adma Biologics ADMA:US $ -14815070 1.62M
Biocryst Pharmaceuticals BCRX:US $ -49957000 2.22M
Chemocentryx CCXI:US $ -38233000 1.82M
Dynavax Technologies DVAX:US $ 31.47M 49.67M
Eli Lilly And LLY:US $ 2569.9M 171.6M
Halozyme Therapeutics HALO:US $ 75.67M 19.14M
Immunogen IMGN:US $ -22852000 11.7M
Insmed INSM:US $ -101451000 1.41M
JAZZ PHA JAZZ:US 87.55M 105.43M
Karyopharm Therapeutics KPTI:US $ -34586000 81.55M
Macrogenics MGNX:US $ -66638000 8.4M
Mannkind MNKD:US $ -23239000 2.29M
Merk MRK:US $ 5059M 207M
Minerva Neurosciences NERV:US $ -7989260 13.39M
Novavax NVAX:US $ 209.29M 1.03B
Novo Nordisk A Fs NVO:US 19.15B 5.51B
Peregrine Pharmaceuticals PPHM:US $ 3.27M 884K
Pfizer PFE:US $ 9995M 4136M
Xencor XNCR:US $ 26.47M 65.19M